- Advanced search
- Immuno Portal
- Malaria Portal
|International Nonproprietary Names|
|CL-2C | NVP-QGE031 | QGE031|
|Ligelizumab is a humanized, investigational high-affinity anti-IgE monoclonal antibody with anti-inflammatory potential , with improved pharmacokinetics and clinical effects compared to omalizumab.
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches with antibody sequences claimed in patent US7531169 B2, where it is the clone designated as CL-2C .
|GtoPdb PubChem SID||310264775|
|Search PubMed clinical trials||ligelizumab|
|Search PubMed titles||ligelizumab|
|Search PubMed titles/abstracts||ligelizumab|